 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- || Myasterix (CV-MG01) / CuraVac
Trial completion, Trial completion date, Trial primary completion date: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - Jan 28, 2019
P1/2, N=24, Completed, Sponsor: CuraVac
Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Sep 2018 | Trial primary completion date: Sep 2019 --> Sep 2018
- | Myasterix (CV-MG01) / CuraVac
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis (clinicaltrials.gov) - May 31, 2018
P2/3, N=0, Withdrawn, Sponsor: CuraVac
Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Sep 2018 | Trial primary completion date: Sep 2019 --> Sep 2018 N=66 --> 0 | Trial completion date: Dec 2018 --> Dec 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2018 --> Oct 2019
- Myasterix (CV-MG01) / CuraVac
Trial primary completion date, IO biomarker: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - Jan 29, 2018
P1/2, N=24, Active, not recruiting, Sponsor: CuraVac
N=66 --> 0 | Trial completion date: Dec 2018 --> Dec 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2018 --> Oct 2019 Trial primary completion date: Sep 2017 --> Sep 2019
- ||||| Myasterix (CV-MG01) / CuraVac
Trial initiation date: A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis (clinicaltrials.gov) - Nov 20, 2017
P2/3, N=66, Not yet recruiting, Sponsor: CuraVac
Trial primary completion date: Sep 2017 --> Sep 2019 Initiation date: Jun 2017 --> Jan 2018
- |||||| Myasterix (CV-MG01) / CuraVac
Enrollment open: A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis (clinicaltrials.gov) - Jun 22, 2017
P2/3, N=66, Recruiting, Sponsor: CuraVac
Initiation date: Jun 2017 --> Jan 2018 Not yet recruiting --> Recruiting
- |||||||||| Myasterix (CV-MG01) / CuraVac
New P2/3 trial: A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis (clinicaltrials.gov) - May 24, 2017
P2/3, N=66, Not yet recruiting, Sponsor: CuraVac
- | Myasterix (CV-MG01) / CuraVac
Trial initiation date, IO biomarker: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - May 12, 2017
P1/2, N=24, Active, not recruiting, Sponsor: CuraVac
Not yet recruiting --> Recruiting Initiation date: Nov 2015 --> Mar 2016
- | Myasterix (CV-MG01) / CuraVac
Enrollment closed, Enrollment change, Trial primary completion date, IO biomarker: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - Mar 21, 2017
P1/2, N=24, Active, not recruiting, Sponsor: CuraVac
Initiation date: Nov 2015 --> Mar 2016 Recruiting --> Active, not recruiting | N=32 --> 24 | Trial primary completion date: Mar 2017 --> Aug 2017
- Myasterix (CV-MG01) / CuraVac
Trial primary completion date, IO biomarker: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - Sep 14, 2016
P1/2, N=32, Recruiting, Sponsor: CuraVac
Recruiting --> Active, not recruiting | N=32 --> 24 | Trial primary completion date: Mar 2017 --> Aug 2017 Trial primary completion date: Sep 2016 --> Mar 2017
- Myasterix (CV-MG01) / CuraVac
New P1/2 trial, IO biomarker: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - Nov 21, 2015
P1/2, N=32, Recruiting, Sponsor: CuraVac